Glutamate and post-traumatic cerebral excitotoxicity as possible therapeutic targets – A literature review

José Luís Alves¹, Anabela Mota Pinto²

Laboratório de Patologia Geral, Faculdade de Medicina da Universidade de Coimbra.

ABSTRACT
Cerebral edema and excitotoxicity are well known phenomena and are reported in multiple pathological contexts. Despite that, regarding traumatic brain injury, significant events in incidence and potential clinical consequences, little is known about the actual promoting and modulating processes of cerebral damage, namely in relation to glutamate, the main excitatory endogenous neurotransmitter of the central nervous system. Based on current concepts on neuropathology and cerebral regulation, a thorough review is made on the glutamatergic regulation system, its role and mechanisms of action in a secondary response to TBI, namely in cortex and hippocampus, sensible areas to acute and delayed damage. Current and past clinical trials are also mentioned as attempts to modulate these events, with no clinical significance so far. A better knowledge of the glutamatergic deregulation and related excitotoxicity should play a key role in the understanding of TBI and provide a basis for possible therapeutic targets in a close future.

KEYWORDS
Glutamic acid, receptors N-methyl-D-aspartate, craniocerebral trauma.

RESUMO
Glutamato e excitotoxicidade cerebral pós-traumática como possíveis alvos terapêuticos – Revisão da literatura
O edema cerebral e a excitotoxicidade são fenômenos bem conhecidos e foram descritos em múltiplos contextos patológicos. Apesar disso, em relação ao traumatismo cranioencefálico (TCE), acontecimento significativo em termos de incidência e consequências clínicas, pouco se sabe acerca dos reais processos de promoção e modulação do dano cerebral, nomeadamente em relação ao glutamato, o principal neurotransmissor excitatório endógeno do sistema nervoso central. Baseando-se em conceitos atuais de Neuropatologia e regulação cerebral, é feita uma revisão do sistema de regulação glutamatérgico, o seu papel e mecanismos de ação na resposta secundária ao TCE, nomeadamente no córtex e hipocampo, áreas propensas ao dano imediato e tardio. São referidos os diferentes ensaios clínicos até a data, como tentativas de modulação desses eventos, sem significância clínica até ao momento. Um melhor conhecimento da desregulação glutamatérgica e concomitante excitotoxicidade deverá desempenhar papel crucial na compreensão do TCE e funcionar como ponto de partida para eventuais alvos terapêuticos no futuro.

PALAVRAS-CHAVE
Ácido glutâmico, receptores de N-metil-D-aspartato, traumatismos craniocerebrais.

¹ Student of Doctoral Program, Faculdade de Medicina da Universidade de Coimbra, Portugal.
² Professor of Pathophysiology, Faculdade de Medicina da Universidade de Coimbra, Portugal.
Introduction

Traumatic brain injury (TBI) is a common clinical condition, one of the most frequent traumatic situations in the pediatric and adult ages, necessarily unforeseen and sudden in progress, with multiple causes (traffic accidents, falls, gunshot wounds) and possibly devastating consequences for the victim and a huge burden for the society, implying huge costs in public health care. Previous reports on humans\(^1,2\) and animal models\(^3,4\) have shown, along with major neurological deficits/symptoms (motor deficits, epilepsy), the persistence of unspecific complaints (namely headaches) and minor cognitive deficits – affected spatial orientation and memory, diminished learning abilities and work performance – directly related to neuronal hippocampal loss.\(^5,6\) These symptoms, obvious after 48h, can persist over two weeks (postconcussion syndrome) and even become permanent.\(^7\) It has also been associated with an increased risk for Depression\(^8\) or neurodegenerative diseases.\(^9\) Emotional processing disturbances can also be attributed to hippocampal damage, according to recent theories on cognitive/mnesic mechanisms and complex emotional states.\(^10\) TBI is the cause of death in 30%-50% of all deaths related to traumatic events,\(^11,12\) with a mortality rate of 18,1/100,000 inhabitants (period 1995-2001), according to CDC (Centers for Disease Control, TBI Surveillance System)\(^13\) (official sources). Even in low-energy trauma, representing 70% to 90% of all TBI’s,\(^13\) the risk for complications or progression of initial injury or cerebral edema poses a significant challenge for the neurosurgeon/neurointensivist. Despite the technology and medical care nowadays increasingly available, it is constantly reminded the need for further tools, capable of guiding the decision process and monitoring, and new therapeutic strategies, effective against self-sustained pathological processes.

Discussion

In TBI, one can distinguish the initial primary events of cellular damage and consequent neurological deficit, including intra-cranial bleeding or cerebral contusions as major primary lesions, and secondary mechanisms of loco-regional, cellular and biochemical deregulation – increased vascular permeability, vascular dilatation, ionic exchanges deregulation – leading to cerebral edema and cellular death (Figure 1). These secondary pathological events, multifactorial in their nature, progress for days after the initial traumatic event and are theoretically subject to pharmacological intervention. It should be mentioned that, although most reports focus on neuronal damage, the concept of astrocyte and glial cell damage is gaining importance, as shown in recent reports,\(^14-17\) with parallel mechanisms of aggression.\(^18,20\) Clinical and animal-model studies with microdialysis\(^21,22\) and spectroscopy\(^27\) (regarding pediatric ages) have shown a significant post-traumatic increase in extracellular levels of glutamate (Figure 2), the main excitatory endogenous neurotransmitter of central nervous system, as well as of lactate (from anaerobic glicolysis)\(^27\) and aspartate.\(^28\) This was also shown in studies of cerebral spinal fluid from TBI victims.\(^29,30\) It should be mentioned that this increase is notorious as early as 6 hours after the trauma\(^27\) but only reaches its peak only around 48h,\(^24\) proving this is not a merely acute event. This increase, described in many hypoxic-ischemic situations in relation to apoptosis/necrosis\(^31\)}

---

**Figure 1 – Acute post-traumatic response and cerebral edema.**

**Figure 2 – Glutamatergic response in post-traumatic damage.**
is attenuated or abolished by induction of barbituric coma,28 which could explain the relative therapeutic role of this last-resort procedure. The levels of extracellular glutamate are regulated by astrocytic transporters GLAST (EAAT1) e GLT-1 (EAAT2),32-34 downregulating the excitotoxic status.35,36 This pathological process leads to damage and cellular death, upon activation of ionotropic receptors NMDA or AMPA – type. More specifically, the activation of these receptors induces disruption of the homeostatic ionic balance, increasing intra-cellular levels of calcium ion (Ca2+) in relation, among other mechanisms, with the high sodium ion (Na+) concentration – revision by Floyd et al.,15 and others37,38 and inversion of the Na+-Ca2+ exchange system (sodium-calcium exchanger, NCX).39 In this way, innumerable enzymatic complexes are activated (phospholipases, endonucleases, proteases), leading to cytoskeleton damage. Other studies, using glutamate-sensitive astrocytic cell cultures40 subject to mechanical trauma, have shown diminished intracellular Na+ levels and improved cellular survival upon glutamate transport inhibition by TBOA (DL-treo-beta-benziloxiaspartate).15 This upset in Ca2+ metabolism, although acute, can last in time, as shown in studies proving delayed changes in Ca2+ homeostasis (30 days after the initial trauma), with rather unknown underlying mechanisms, in possible relation to clinical findings like post-traumatic seizures.38 Adding to this, following initial cell injury, one can also observe mitochondrial damage and release of oxygen reactive species (ROS), promoting apoptosis, documented in TBI animal models from 2h to two weeks after the initial trauma.41 The increase in ROS release in an ischemic event, as a starting point for oxidative stress, is apparently the result of high extracellular glutamate levels.35,42,43 ROS are responsible for abnormal protein turnover, upsetting its normal function and interfering with cellular cycles, damaging DNA (breaks in chain or changes in the nucleotides components) (Figure 2). Different studies addressing the use of antioxidant agents in ischemic events failed to show encouraging results.42 Cell`s structural damage eventually will imply inversion of the normal function of glutamate receptors, on a neuronal and astrocytic level, in part due to ATP depletion as a result of iNOS-mediated (inducible nitric oxide synthase)44,45 nitric oxide release, with additional glutamate release to the extracellular compartment.46-48 Cellular damage, diminished glutamate uptake by sodium-dependent carriers,49 augmented extracellular/synaptic levels of glutamate, they all contribute to increased cell injury or death, which will then result in reduced glutamate uptake and its increased spilling, promoting a self-sustained process of neuronal/astrocytic aggression (Figure 2) (vicious circle)48,49 documented in several clinical contexts: TBI, medullary lesions, ischemic events, neurodegenerative diseases.24,50-52 These increasingly disseminated events, promoting secondary damage, are in part responsible for the pathological changes in structures topographically distant from the initial trauma (e.g. contra-lateral hippocampus), being a potential therapeutic target in an attempt to stop or attenuate the phenomena leading to secondary, possibly permanent, damage (Figure 3). The pre-synaptic deregulation might itself be related to circuit alterations,48 leading to behavioral changes and stimulus hypersensitivity, shown in animal models and humans victims of TBI.

Along with the frequent cortical contusion (or similar injury) and white matter tracts ultra-structural damage,53 several experimental studies on TBI show significant damage to the ipsi and contra-lateral hippocampus,54-56 including neuronal disruption on layer CA3 (up to 60%) in the first 48h57 and deafferentation in the CA1 layer. Immunohistochemical assays – GFAP and Fluor-Jade staining – confirm neuronal and astrocytic structural damage, namely in the layers previously mentioned – CA1 and CA3 – in the first 24h after TBI.59 However, hippocampal damage is also observed in cell populations that, although not on necrosis/apoptosis processes, present several minor structural damages, including synaptic and dendritic degeneration, with diminished local synaptic density.57 In animal models of repetitive minor TBI, disperse gliosis and minimal changes in the deeper layers were shown.58 In several experimental models of post-traumatic hippocampal apoptotic phenomena, two distinct stages are obvious: an initial one – cellular damage and loss, followed by a progressive neuronal loss, persisting for days or even weeks59,60 (Figure 3). Hippocampal neuronal loss, as well as lower threshold for excitability, is obvious bilaterally but only really persisting (30 days) on the same side of the impact.61 Pyramidal CA3-layer and dentate gyrus hippocampal neurons appear to be most vulnerable to this bilateral degeneration59 following unilateral trauma, as a result of systemic repercussion of an initially localized event. The most frequent post-TBI cognitive impairment, memory disturbance, as well as spatial learning, can therefore be explained on anatomic-pathological grounds, regarding structural disruption, disturbance of neurometabolic equilibrium (documented in concussion-victims athletes submitted to MRI-spectroscopy62 and interference with normal hippocampal synaptic transmission,63,64 including raised excitability potential65 48h after TBI.

Hippocampal damage is amplified, as expected, with low doses of keinate receptor agonists, glutamate analogues.66 This can explain the neuroprotective effect, in animal models, of NMDA and AMPA-receptor antagonists67 facing an initial hypoxic-ischemic aggression,48 manifested by diminished cortical and hip-
pocampal (mostly CA1 layer) neuronal loss. However, as with every clinical trials with neuroprotective agents in trauma, tests with Sefotel (CGS-19755) or Traxoprodil (CP-101606), NMDA-receptors antagonists, failed to show any improvement in morbidity and/or mortality. Other therapeutic targets were tested in animal models, including neuropeptide Substance P, a modulator for Glutamate levels and NMDA receptors, using Neurokinin antagonists and cannabinoid receptors type 2 antagonists, with promising results regarding functional outcome.

The transition from animal experimental models to large prospective clinical trials has failed showing significant efficacy for these therapeutic agents, and none is included in the diverse daily-practice clinical protocols. Many reasons have been pointed for this: insufficient knowledge on pathophysiology, unknown optimal dosages and therapeutic timings, incorrect pharmacological preparation, arguable end-points, basic anatomical and physiological differences between human and animal models of disease, among many others.

### References

Correspondence address
José Luís Alves
Laboratório de Patologia Geral,
Faculdade de Medicina da Universidade de Coimbra
Rua Larga, 3004-504
Coimbra, Portugal
Telefone +351-239 857 777
E-mail: jlmonteiroalves@gmail.com